Covestor’s Zevra Therapeutics ZVRA Stock Holding History

Covestor’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1K	Buy	56 +34	+155%	+$378	﹤0.01%	2400
2026 Q1	$0	Buy	+22	New	+$198	﹤0.01%	2847

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Covestor's ZVRA Position: Q2 2026 in Review

Covestor increased its Zevra Therapeutics (ZVRA) stake by 155% in Q2 2026, buying an estimated $378 and bringing the position to 56 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #2400.

Covestor first reported a position in ZVRA in Q1 2026 and has held it in 2 quarters since. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

Covestor held 56 shares of Zevra Therapeutics worth $1K as of Q2 2026.
Covestor bought 34 Zevra Therapeutics shares in Q2 2026, an estimated $378.
Zevra Therapeutics made up ﹤0.01% of Covestor's portfolio in Q2 2026, its #2400 holding.
Covestor first reported a position in Zevra Therapeutics in Q1 2026 and has held it in 2 quarters since.
157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.